Gennex Laboratories Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 5/6
Gennex Laboratories has been growing earnings at an average annual rate of 39.5%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 7.3% per year. Gennex Laboratories's return on equity is 8.5%, and it has net margins of 15.2%.
Key information
39.5%
Earnings growth rate
29.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 7.3% |
| Return on equity | 8.5% |
| Net Margin | 15.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gennex Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 985 | 150 | 76 | 0 |
| 31 Mar 24 | 867 | 132 | 79 | 0 |
| 31 Dec 23 | 719 | 107 | 90 | 0 |
| 30 Sep 23 | 666 | 90 | 91 | 0 |
| 30 Jun 23 | 682 | 70 | 85 | 0 |
| 31 Mar 23 | 656 | 49 | 81 | 0 |
| 31 Dec 22 | 671 | 40 | 82 | 0 |
| 30 Sep 22 | 697 | 37 | 76 | 0 |
| 30 Jun 22 | 648 | 37 | 72 | 0 |
| 31 Mar 22 | 612 | 39 | 73 | 0 |
| 31 Dec 21 | 576 | 44 | 72 | 0 |
| 30 Sep 21 | 564 | 49 | 77 | 0 |
| 30 Jun 21 | 575 | 46 | 73 | 0 |
| 31 Mar 21 | 596 | 40 | 74 | 0 |
| 31 Dec 20 | 552 | 28 | 70 | 0 |
| 30 Sep 20 | 545 | 17 | 70 | 0 |
| 30 Jun 20 | 530 | 14 | 70 | 0 |
| 31 Mar 20 | 562 | 19 | 71 | 0 |
| 31 Dec 19 | 653 | 20 | 73 | 0 |
| 30 Sep 19 | 658 | 27 | 70 | 0 |
| 30 Jun 19 | 634 | 25 | 65 | 0 |
| 31 Mar 19 | 563 | 22 | 63 | 0 |
| 31 Dec 18 | 498 | 16 | 64 | 0 |
| 30 Sep 18 | 464 | 10 | 59 | 0 |
| 30 Jun 18 | 460 | 10 | 58 | 0 |
| 31 Mar 18 | 443 | 8 | 57 | 0 |
| 31 Dec 17 | 429 | 8 | 54 | 0 |
| 30 Sep 17 | 410 | 15 | 54 | 0 |
| 30 Jun 17 | 421 | 25 | 53 | 0 |
| 31 Mar 17 | 419 | 27 | 51 | 0 |
| 31 Dec 16 | 408 | 32 | 47 | 0 |
| 30 Sep 16 | 393 | 31 | 46 | 0 |
| 30 Jun 16 | 370 | 25 | 42 | 0 |
| 31 Mar 16 | 386 | 23 | 43 | 0 |
| 31 Dec 15 | 379 | 21 | 61 | 0 |
| 30 Sep 15 | 354 | 12 | 59 | 0 |
| 30 Jun 15 | 335 | 8 | 66 | 0 |
| 31 Mar 15 | 319 | 7 | 35 | 0 |
| 31 Dec 14 | 326 | 1 | 62 | 0 |
| 30 Sep 14 | 361 | 7 | 61 | 0 |
| 30 Jun 14 | 359 | 5 | 32 | 0 |
| 31 Mar 14 | 350 | 2 | 59 | 0 |
| 31 Dec 13 | 334 | 10 | 45 | 0 |
Quality Earnings: 531739 has high quality earnings.
Growing Profit Margin: 531739's current net profit margins (15.2%) are higher than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531739's earnings have grown significantly by 39.5% per year over the past 5 years.
Accelerating Growth: 531739's earnings growth over the past year (113.5%) exceeds its 5-year average (39.5% per year).
Earnings vs Industry: 531739 earnings growth over the past year (113.5%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 531739's Return on Equity (8.5%) is considered low.